


pLAPSN Retroviral Vector Information

PT3135-5

GenBank Accession No.: Submission in progress.

Sold as part of Catalog No. K1060-A



Restriction Map of pLAPSN Retroviral Vector. Unique restriction sites are in bold.

Description

pLAPSN contains elements derived from Moloney murine leukemia virus (MoMuLV) and Moloney murine sarcoma virus (MoMuSV), and is a control vector for establishing a retroviral gene delivery and expression system (1–3). This vector was created by cloning the gene for human placenta alkaline phosphatase (AP) into the *Xho* I site in the multiple cloning site of the pLXSN Retroviral Vector (Cat. No. 631509). Upon transfection into a packaging cell line, pLAPSN can transiently express, or integrate and stably express, a transcript containing Ψ^+ (the extended viral packaging signal) the human placenta alkaline phosphatase gene, and a selectable marker. The 5' viral LTR in this vector contains promoter/enhancer sequences that control expression of the alkaline phosphatase gene. The SV40 early promoter (P_{SV40e}) controls expression of the neomycin resistance gene (Neo^r), which allows antibiotic selection in eukaryotic cells. pLAPSN also includes the Col E1 origin of replication and *E. coli* Amp^r gene for propagation and antibiotic selection in bacteria.

Use

pLAPSN can be used in control experiments to establish retroviral gene transduction procedures. After being transfected into a packaging cell line (such as the RetroPack PT67 Cell Line, Cat. No. 631510), RNA from the vector is packaged into infectious, replication-incompetent retroviral particles. pLAPSN does not contain the structural genes (*gag*, *pol*, and *env*) necessary for particle formation and replication; however, these genes are stably integrated into PT67 (4–7). Subsequent introduction of pLAPSN, containing Ψ^+ (psi), transcription and processing elements, and the alkaline phosphatase gene, produces high-titer, replication-incompetent infectious virus. That is, these retroviral particles can infect target cells and transmit the alkaline phosphatase gene, but cannot replicate within these cells since the cells lack the viral structural genes. The separate introduction and integration of the structural genes into the packaging cell line minimizes the chances of producing replication-competent virus due to recombination events during cell proliferation. The expression of alkaline phosphatase can be confirmed using a standard assay.



Clontech

United States/Canada
800.662.2566

Asia Pacific
+1.650.919.7300

Europe
+33.(0)1.3904.6880

Japan
+81.(0)77.543.6116

Clontech Laboratories, Inc.
A Takara Bio Company
1290 Terra Bella Ave.
Mountain View, CA 94043
Technical Support (US)
E-mail: tech@clontech.com
www.clontech.com

(PR19382; published 08 October 2001)

Location of Features

- 5' MoMuSV LTR: 1–589
- Ψ^+ (extended packaging signal): 659–1468
Mutated *gag* (ATG→TAG): 1049–1051
- Fragment containing the alkaline phosphatase (AP) gene: 1558–3150
- Early SV40 promoter (P_{SV40e}): 3467–3819
- Neomycin resistance gene (Neo^r):
Start codon: 3865–3867; stop codon: 4657–4659
- 3' MoMuLV LTR: 4719–5312
- Col E1 origin of replication:
Site of replication initiation: 5848
- Ampicillin resistance gene (β -lactamase):
Start codon: 7468–7466; stop codon: 6610–6608

Propagation in *E. coli*

- Suitable host strains: DH5 α , HB101, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 μ g/ml) to *E. coli* hosts.
- *E. coli* replication origin: Col E1
- Copy number: low

References

1. Coffin, J. M. & Varmus, H. E., eds. (1996) *Retroviruses* (Cold Spring Harbor Laboratory Press, NY).
2. Ausubel, F. M., et al. (1994) *Current Protocols in Molecular Biology* (Greene Publishing Associates, Inc. & John Wiley & Sons, Inc.).
3. Miller, A. D. & Rosman, G. J. (1989) *BioTechniques* **7**:980–990.
4. Mann, R., et al. (1983) *Cell* **33**:153–159.
5. Miller, A. D. & Buttimore, C. (1986) *Mol. Cell. Biol.* **6**:2895–2902.
6. Morgenstern, J. P. & Land, H. (1990) *Nucleic Acids Res.* **18**:3587–3590.
7. Miller, A. D. & Chen, F. (1996) *J. Virol.* **70**:5564–5571.

Notes: The viral supernatants produced by this retroviral vector could, depending on your cloned insert, contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant retrovirus. Appropriate NIH, regional, and institutional guidelines apply.

The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Retroviral Vectors are sold under license from the Fred Hutchinson Cancer Research Center. Rights to use this product are limited to research only. No other rights are conveyed. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Fred Hutchinson Cancer Research Center, Technology Transfer Office, 1100 Fairview Avenue North, J6-200, Seattle, WA 98109. Purchase of this product does not grant rights to: (1) offer the materials or any derivatives thereof for resale; or (2) to distribute or transfer the materials or any derivatives thereof to third parties.

The RetroPack™ PT67 Cell Line is covered under U.S. Patent No. 5,766,945, which has been assigned to the Fred Hutchinson Cancer Research Center. Rights to use this product are limited to research only. No other rights are conveyed. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Fred Hutchinson Cancer Research Center, Technology Transfer Office, 1100 Fairview Avenue North, J6-200, Seattle, WA 98109. Purchase of this product does not grant rights to: (1) offer the materials or any derivatives thereof for resale; or (2) to distribute or transfer the materials or any derivatives thereof to third parties.

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc. Clontech is a Takara Bio Company. ©2006